For the distinction between a renal cell origin and a non-renal origin of tumors (including all other tumor entities of our study), sensitivity was 88.1% and specificity 87.2% for PAX8, while sensitivity was 85.3% and specificity 95.7% for CDH16. This evidence concerns the gene PAX8 and neoplasm.